Abstract Number: 831 • 2012 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab (AMG 827) in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Background/Purpose: A potential role for IL-17 in rheumatoid arthritis (RA) has been supported by data from clinical studies of inhibitors of the IL-17A ligand. To…Abstract Number: 360 • 2012 ACR/ARHP Annual Meeting
Initial Introduction of Treat-to-Target Strategy in Patients with Recent Onset Rheumatoid Arthritis Is More Effective Than Delayed Introduction of Strategy with More Clinical and Functional Remission Achieved for 2-Years: Results of the Treating to Twine Targets (T-4) Study
Background/Purpose: To compare the clinical, radiological and functional efficacy of initial versus delayed introduction of strategy which is treat-to-target to patients with recent onset rheumatoid…Abstract Number: 2149 • 2012 ACR/ARHP Annual Meeting
Atsttrin-â, an Engineered Protein Derived From Progranulin Growth Factor, Binds to TNF Receptors and Exhibits Potent Anti-Inflammatory Activity in Mice
Background/Purpose: Progranulin (PGRN) is a multifunctional growth factor. Recently, we reported that PGRN and its derived protein Atsttrin-α (referred to as “Atsttrin” in our previous…Abstract Number: 1298 • 2012 ACR/ARHP Annual Meeting
Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach
Background/Purpose: Salazosulfapyridine (SASP) is acetylated in liver by N-acetyltransferase2 (NAT2) in the track of metabolism. Previous studies have shown that genotyping of NAT2 is adequate…Abstract Number: 773 • 2012 ACR/ARHP Annual Meeting
Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This analysis evaluated the rates…Abstract Number: 369 • 2012 ACR/ARHP Annual Meeting
Differences in Short-Term Radiographic Progression Following Early Response to Adalimumab Plus Methotrexate Vs. Methotrexate Alone
Background/Purpose: To prevent disease progression, treat-to-target recommendations for rheumatoid arthritis (RA) include the evaluation and adjustment of drug therapy at least every 3 months until…Abstract Number: 1846 • 2012 ACR/ARHP Annual Meeting
Observation of Persistence Rates and Potential Costs Savings Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northen Ireland Clinical Practice
Background/Purpose: Rheumatoid arthritis (RA) therapy in the UK is standardized by the National Institute for Health and Clinical Excellence (NICE). To be eligible for anti-TNF…Abstract Number: 1312 • 2012 ACR/ARHP Annual Meeting
Clinical Response At 12 Weeks Predicts Long-Term Remission and the Extent of Radiographic Progression in Japanese Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol with and without Methotrexate Coadministration
Background/Purpose: The majority of patients (pts) with active rheumatoid arthritis (RA) have previously been shown to respond during the first 12 weeks (wks) of certolizumab…Abstract Number: 774 • 2012 ACR/ARHP Annual Meeting
A CD4+ T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis
Background/Purpose: The mechanism of action of methotrexate (MTX) in the management of rheumatoid arthritis (RA) remains incompletely understood. It is nonetheless capable of inducing clinical…Abstract Number: 331 • 2012 ACR/ARHP Annual Meeting
PDL241, a Novel Humanized Monoclonal Antibody, Reveals CD319 As a Therapeutic Target for Rheumatoid Arthritis
Background/Purpose: Current therapies have shown tremendous progress in the treatment of rheumatoïd arthritis (RA). However, a substantial group of RA patients are still refractory to…Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting
Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…Abstract Number: 1279 • 2012 ACR/ARHP Annual Meeting
First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis
Background/Purpose: Interleukin-21 (IL-21), a cytokine produced by activated T cells (especially T17 and TFH cells), has a proinflammatory and pleiotropic nature, and drives mainly activation…Abstract Number: 776 • 2012 ACR/ARHP Annual Meeting
A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission
Background/Purpose: Treatment with TNF blockers, once started as therapy for RA, is usually continued indefinitely. Information about the possibility to discontinue anti-TNF therapy in RA…Abstract Number: 336 • 2012 ACR/ARHP Annual Meeting
Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody® For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor IL-6R. IL-6 plays an important role in the…Abstract Number: 1831 • 2012 ACR/ARHP Annual Meeting
Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database
Background/Purpose: Rheumatoid arthritis (RA), a chronic inflammatory disorder, causes a significant decrease in quality of life. Recently developed biologic agents (BAs) have caused a considerable…
ACR Meeting Abstracts